Afzanna 30mg Tablet

Afzanna 30mg tablet is a targeted based therapy designed to specifically attack cancer cells with EGFR mutations, helping to slow or stop their growth and multiplication. This anti-cancer medication is used treat non-small cell lung cancer, its active ingredients is Afatinib, present in its salt form. The medication should be taken according to the doctor to ensure maximum effectiveness and safety. It is not used alone and not in combination with other medication, as it is prescribed as a monotherapy. Afzanna 30mg tablet is strictly prescribed by the healthcare provider.

Non small cell lung cancer

Afzanna 30mg tablet has various side effects like any other medication has. Some of the patients do not experience any symptoms but some need proper treatment to recover. Visit the doctor instantly if the symptoms persist:
● Diarrhea
● Rash
● Dry skin
● Vomiting
● Itching
● Nail disorder
● Nausea
● Loss of appetite
● Stomatitis
● Headache

Afzanna tablet is highly recommended to lung cancer patients which can be taken on an empty stomach at the same time everyday. Do not chew, crush just swallow the whole tablet at once. Guidance from the healthcare expert is much needed to ensure safety and enhance the effectiveness of the medication. Never skip or double the dose to make up for the missed one, as this may increase the risk of side effects.

Lung cancer contain EGFR gene which cause abnormal cell growth and uncontrolled multiplication of cancer cells in the body. Afzanna 30mg tablet block endothelial growth factor receptor, which is responsible for the growth and multiplication of cancer cells in the body. The medication is targeted therapy which directly targets the tumor growth but does not damage the healthy cells that increase the effectiveness of the treatment.

• Park, K., Tan, E. H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., ... & Paz-Ares, L. (2016). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology, 17(5), 577-589.
• Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., ... & Adolf, G. R. (2012). Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. The Journal of pharmacology and experimental therapeutics, 343(2), 342-350.
• Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020). Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of Oncology Pharmacy Practice, 26(6), 1461-1474.
• Schuler, M., Yang, J. H., Park, K., Kim, J. H., Bennouna, J., Chen, Y. M., ... & Popovych, O. (2016). Afatinib beyond progressio
• Yang, J. C. H., Shih, J. Y., Su, W. C., Hsia, T. C., Tsai, C. M., Ou, S. H. I., ... & Miller, V. A. (2012). Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. The lancet oncology, 13(5), 539-548.